{"id":812729,"date":"2025-02-13T08:18:22","date_gmt":"2025-02-13T13:18:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/"},"modified":"2025-02-13T08:18:22","modified_gmt":"2025-02-13T13:18:22","slug":"merus-to-present-at-citis-2025-virtual-oncology-leadership-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/","title":{"rendered":"Merus to Present at Citi’s 2025 Virtual Oncology Leadership Summit"},"content":{"rendered":"
\n

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) — Merus N.V<\/a>. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi’s 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET.<\/p>\n

The webcast of the presentation will be contemporaneously available on the Investors page<\/a> of the Company’s website. The archived presentation will also be available there for a limited time after the event.<\/p>\n

\n
\n About Merus<\/strong>
\n <\/strong>
\n
\n Merus<\/a> is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics\u00ae<\/a>. Multiclonics\u00ae are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus\u2019 website<\/a> and LinkedIn<\/a>.<\/p>\n

Multiclonics\u00ae, Biclonics\u00ae and Triclonics\u00ae are registered trademarks of Merus N.V.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
Investor and Media Inquiries:\r\nSherri Spear\r\nMerus N.V.\r\nSVP Investor Relations and Strategic Communications\r\n617-821-3246\r\ns.spear@merus.nl\r\n\r\nKathleen Farren\r\nMerus N.V.\r\nAssoc. Director IR\/Corp Comms\r\n617-230-4165\r\nk.farren@merus.nl<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi’s 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event. About Merus Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics\u00ae. Multiclonics\u00ae are manufactured using industry standard processes and have … <\/p>\n
Continue reading “Merus to Present at Citi’s 2025 Virtual Oncology Leadership Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-812729","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMerus to Present at Citi's 2025 Virtual Oncology Leadership Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi’s 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event. About Merus Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics\u00ae. Multiclonics\u00ae are manufactured using industry standard processes and have … Continue reading "Merus to Present at Citi’s 2025 Virtual Oncology Leadership Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-13T13:18:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Merus to Present at Citi’s 2025 Virtual Oncology Leadership Summit\",\"datePublished\":\"2025-02-13T13:18:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/\"},\"wordCount\":172,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/\",\"name\":\"Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc=\",\"datePublished\":\"2025-02-13T13:18:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merus to Present at Citi’s 2025 Virtual Oncology Leadership Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/","og_locale":"en_US","og_type":"article","og_title":"Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - Market Newsdesk","og_description":"UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi’s 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event. About Merus Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics\u00ae. Multiclonics\u00ae are manufactured using industry standard processes and have … Continue reading \"Merus to Present at Citi’s 2025 Virtual Oncology Leadership Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-13T13:18:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Merus to Present at Citi’s 2025 Virtual Oncology Leadership Summit","datePublished":"2025-02-13T13:18:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/"},"wordCount":172,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/","name":"Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc=","datePublished":"2025-02-13T13:18:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUyNiM2NzQ4NTQxIzIwMjAyODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-citis-2025-virtual-oncology-leadership-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Merus to Present at Citi’s 2025 Virtual Oncology Leadership Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=812729"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812729\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=812729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=812729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=812729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}